» Articles » PMID: 38687509

EIF3B Stabilizes PCNA by Counteracting SYVN1-mediated Ubiquitination to Serve As a Promotor in Cholangiocarcinoma

Overview
Specialty Geriatrics
Date 2024 Apr 30
PMID 38687509
Authors
Affiliations
Soon will be listed here.
Abstract

Cholangiocarcinoma, a prevalent hepatic malignancy, exhibits a progressively rising incidence. While Eukaryotic translation initiation factor 3 subunit B (EIF3B) has been implicated in the occurrence and development of various cancers, its specific roles in cholangiocarcinoma remain unexplored. Immunohistochemical (IHC) analysis was employed to detect EIF3B/PCNA expression in cholangiocarcinoma. Cells were manipulated using short hairpin RNA (shRNA)-mediated lentiviruses or overexpression plasmids. Statistical significance was assessed using the Student's t-test and one-way ANOVA, with P < 0.05 considered statistically significant. EIF3B exhibited robust expression in cholangiocarcinoma, demonstrating a significant correlation with the pathological grade of cholangiocarcinoma patients. Furthermore, modulation of EIF3B expression, either depletion or elevation, demonstrated the ability to inhibit or enhance cholangiocarcinoma cell survival and migration . Mechanistically, we identified Proliferating Cell Nuclear Antigen (PCNA) as a downstream gene of EIF3B, driving cholangiocarcinoma. EIF3B stabilized PCNA by inhibiting PCNA ubiquitination, a process mediated by E3 ligase SYVN1. Similar to EIF3B, PCNA levels were also abundant in cholangiocarcinoma, and knocking down PCNA impeded cholangiocarcinoma development. Intriguingly, silencing PCNA attenuated the promotion induced by EIF3B overexpression. Furthermore, the elevated P21 protein level in shEIF3B RBE cells was partially attenuated after UC2288 (P21 signaling pathway inhibitor) treatment. Our findings underscored the potential of EIF3B as a therapeutic target for cholangiocarcinoma. Unraveling its functions holds promise for the development of more specific and effective targeted therapy strategies.

Citing Articles

FOXA1-dependent PUS1 regulates EIF3b stability in a non-enzymatic pathway mediating prostate cancer bone metastasis.

Wu Y, Peng S, Cheng B, Zhong H, Cen M, Fu J Int J Biol Sci. 2024; 20(11):4566-4584.

PMID: 39247811 PMC: 11380452. DOI: 10.7150/ijbs.100905.

References
1.
Miyachi K, Fritzler M, Tan E . Autoantibody to a nuclear antigen in proliferating cells. J Immunol. 1978; 121(6):2228-34. View

2.
Borad M, Champion M, Egan J, Liang W, Fonseca R, Bryce A . Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma. PLoS Genet. 2014; 10(2):e1004135. PMC: 3923676. DOI: 10.1371/journal.pgen.1004135. View

3.
Chen G, Burger M . p150 overexpression in gastric carcinoma: the association with p53, apoptosis and cell proliferation. Int J Cancer. 2004; 112(3):393-8. DOI: 10.1002/ijc.20443. View

4.
Dellas A, Torhorst J, Bachmann F, Banziger R, Schultheiss E, Burger M . Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer. 1998; 83(7):1376-83. DOI: 10.1002/(sici)1097-0142(19981001)83:7<1376::aid-cncr15>3.0.co;2-1. View

5.
Endo I, Gonen M, Yopp A, Dalal K, Zhou Q, Klimstra D . Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008; 248(1):84-96. DOI: 10.1097/SLA.0b013e318176c4d3. View